ANI Pharmaceuticals reports Q3 2026 earnings beat, raises full‑year guidance and announces two acquisitions
+1 new source since this summary was written
ANI Pharmaceuticals posted Q3 2026 revenue of $290.8 million, a 27.6% year‑over‑year increase, and adjusted earnings of $2.70 per share, beating expectations. The company lifted its FY 2026 adjusted EPS guidance to $9.37‑$9.71 and its revenue guidance to $1.08‑$1.12 billion, while also reaffirming a $1.11 billion target. It disclosed a $434 million acquisition of Egetis, slated to close late 2026, and an offer to acquire Aegidus Therapeutics, and revised Cortrophin Gel revenue guidance to $480‑$500 million.
Why it matters
The higher EPS and revenue forecasts suggest stronger profitability and top‑line growth, which may improve valuation expectations (the company raised its FY 2026 EPS guidance). The announced acquisitions expand ANI’s rare‑disease pipeline, potentially adding over $300 million of peak sales from Egetis’s EMCITATE and diversifying its portfolio.
Key facts
- 1Q3 2026 revenue was $290.8 million, up 27.6% year‑over‑year. tradingview.com
- 2Adjusted EPS for Q3 2026 was $2.70 per share. finance.yahoo.com
- 3Net income for Q3 2026 was $35.15 million. tradingview.com
- 4FY 2026 adjusted EPS guidance was raised to $9.37‑$9.71 per share. finance.yahoo.com
- 5FY 2026 revenue guidance was raised to $1.08 billion‑$1.12 billion. investing.com
- 6The company reaffirmed a FY 2026 revenue target of $1.11 billion. finance.yahoo.com
Open questions
- FY 2026 revenue guidance ranges differ: $1.08‑$1.12 billion, $1.11 billion, and $1.085‑$1.125 billion.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.